Transcatheter versus surgical aortic valve replacement in patients with diabetes and severe aortic stenosis at high risk for surgery: an analysis of the PARTNER Trial (Placement of Aortic Transcatheter Valve).

MedStar author(s):
Citation: Journal of the American College of Cardiology. 63(11):1090-9, 2014 Mar 25.PMID: 24291272Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Comparative Study | Journal Article | Randomized Controlled Trial | Research Support, N.I.H., Extramural | Research Support, Non-U.S. Gov'tSubject headings: *Aortic Valve Stenosis/th [Therapy] | *Cardiac Catheterization/mt [Methods] | *Diabetes Mellitus, Type 2/di [Diagnosis] | *Heart Valve Prosthesis Implantation/mt [Methods] | *Hospital Mortality | Age Factors | Aged | Aged, 80 and over | Aortic Valve Stenosis/co [Complications] | Aortic Valve Stenosis/mo [Mortality] | Aortic Valve Stenosis/su [Surgery] | Diabetes Mellitus, Type 2/co [Complications] | Diabetes Mellitus, Type 2/mo [Mortality] | Echocardiography, Doppler | Evaluation Studies as Topic | Female | Follow-Up Studies | Heart Valve Prosthesis | Heart Valve Prosthesis Implantation/mo [Mortality] | Humans | Kaplan-Meier Estimate | Male | Postoperative Complications/mo [Mortality] | Postoperative Complications/pc [Prevention & Control] | Proportional Hazards Models | Risk Assessment | Severity of Illness Index | Sex Factors | Statistics, Nonparametric | Surgical Procedures, Minimally Invasive/mo [Mortality] | Surgical Procedures, Minimally Invasive/mt [Methods] | Survival Rate | Treatment OutcomeYear: 2014Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007ISSN:
  • 0735-1097
Name of journal: Journal of the American College of CardiologyAbstract: BACKGROUND: Diabetes is associated with increased morbidity and mortality after surgical AVR for AS.CONCLUSIONS: Among patients with diabetes and severe symptomatic AS at high risk for surgery, this post-hoc stratified analysis of the PARTNER trial suggests there is a survival benefit, no increase in stroke, and less renal failure from treatment with transcatheter AVR compared with surgical AVR. (The PARTNER Trial: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894). Copyright 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.METHODS: Among treated patients with severe symptomatic AS at high risk for surgery in the PARTNER (Placement of Aortic Transcatheter Valve) trial, we examined outcomes stratified according to diabetes status of patients randomly assigned to receive transcatheter or surgical AVR. The primary outcome was all-cause mortality at 1 year.OBJECTIVES: The goal of this study was to determine whether a less-invasive approach to aortic valve replacement (AVR) improves clinical outcomes in diabetic patients with aortic stenosis (AS).RESULTS: Among 657 patients enrolled in PARTNER who underwent treatment, there were 275 patients with diabetes (145 transcatheter, 130 surgical). There was a significant interaction between diabetes and treatment group for 1-year all-cause mortality (p = 0.048). Among diabetic patients, all-cause mortality at 1 year was 18.0% in the transcatheter group and 27.4% in the surgical group (hazard ratio: 0.60 [95% confidence interval: 0.36 to 0.99]; p = 0.04). Results were consistent among patients treated via transfemoral or transapical routes. In contrast, among nondiabetic patients, there was no significant difference in all-cause mortality at 1 year (p = 0.48). Among diabetic patients, the 1-year rates of stroke were similar between treatment groups (3.5% transcatheter vs. 3.5% surgery; p = 0.88), but the rate of renal failure requiring dialysis >30 days was lower in the transcatheter group (0% vs. 6.1%; p = 0.003).All authors: Arnold SV, Kirtane AJ, Kodali S, Leon MB, Lindman BR, Maniar HS, McAndrew TC, Pibarot P, Smith CR, Suri RM, Svensson LG, Thourani VH, Tuzcu EM, Waksman R, Zajarias AFiscal year: FY2014Digital Object Identifier: Date added to catalog: 2014-08-21
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 24291272 Available 24291272

Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007

BACKGROUND: Diabetes is associated with increased morbidity and mortality after surgical AVR for AS.

CONCLUSIONS: Among patients with diabetes and severe symptomatic AS at high risk for surgery, this post-hoc stratified analysis of the PARTNER trial suggests there is a survival benefit, no increase in stroke, and less renal failure from treatment with transcatheter AVR compared with surgical AVR. (The PARTNER Trial: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894). Copyright 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

METHODS: Among treated patients with severe symptomatic AS at high risk for surgery in the PARTNER (Placement of Aortic Transcatheter Valve) trial, we examined outcomes stratified according to diabetes status of patients randomly assigned to receive transcatheter or surgical AVR. The primary outcome was all-cause mortality at 1 year.

OBJECTIVES: The goal of this study was to determine whether a less-invasive approach to aortic valve replacement (AVR) improves clinical outcomes in diabetic patients with aortic stenosis (AS).

RESULTS: Among 657 patients enrolled in PARTNER who underwent treatment, there were 275 patients with diabetes (145 transcatheter, 130 surgical). There was a significant interaction between diabetes and treatment group for 1-year all-cause mortality (p = 0.048). Among diabetic patients, all-cause mortality at 1 year was 18.0% in the transcatheter group and 27.4% in the surgical group (hazard ratio: 0.60 [95% confidence interval: 0.36 to 0.99]; p = 0.04). Results were consistent among patients treated via transfemoral or transapical routes. In contrast, among nondiabetic patients, there was no significant difference in all-cause mortality at 1 year (p = 0.48). Among diabetic patients, the 1-year rates of stroke were similar between treatment groups (3.5% transcatheter vs. 3.5% surgery; p = 0.88), but the rate of renal failure requiring dialysis >30 days was lower in the transcatheter group (0% vs. 6.1%; p = 0.003).

English

Powered by Koha